> ## Content Index > Fetch the complete content index at: https://www.bullished.co/llms.txt > Use this file to discover other available public pages before exploring further. # Merck Is 22% Of Personalis Revenue — And A Related Party Voting For The Tempus Deal - URL: https://www.bullished.co/merck-is-22-of-personalis-revenue-and-a-related-party-voting-for-the-tempus-deal-9c683ff7/ - Published: 2026-11-04T22:12:29.000Z - Updated: 2026-11-04T22:12:29.000Z - Description: Personalis's largest customer owns more than 10% of its stock, and Tempus fees inside selling costs have jumped to $4.8 million. - Author: Matteo Parrino - Tags: SEC Filings, PSNL, Industry: Healthcare Merck, a holder of more than 10% of [Personalis](https://www.bullished.co/tag/psnl/) stock, supplied [22% of the company's third-quarter revenue](https://www.sec.gov/Archives/edgar/data/0001527753/000119312526447201/psnl-20260930.htm?ref=bullished.co), according to its 10-Q filed Wednesday. Personalis, which sells advanced cancer genomic testing, is heading to a November 30 stockholder vote on its sale to Tempus, the other related party in its books. ## A customer that is also an owner The company classes Merck and Tempus as related parties because each owns more than 10% of its common stock. Merck accounted for 27% of revenue over the first nine months of 2026. Related-party revenue was $5.9 million in the quarter, against $1.1 million a year earlier, and $17.4 million for nine months, against $3.5 million. The company said the rise in pharma testing revenue came mainly from more clinical trial samples processed for Merck. [Merck owed Personalis $4.0 million](https://www.businesswire.com/news/home/20261104890700/en/Personalis-Reports-Third-Quarter-Results?ref=bullished.co) at September 30, against $2.0 million at December 31, 2025\. Total quarterly revenue was $25.6 million, up from $14.5 million. ## Tempus fees double selling costs Tempus, which is buying Personalis, was paid $4.8 million in order and results-delivery fees in the quarter, up from $1.2 million. Those fees sit inside selling, general and administrative expense, which reached $26.0 million from $13.0 million a year earlier. Of the third-quarter increase in that line, $4.3 million came from fees payable to Tempus, and [$4.0 million from professional services](https://www.businesswire.com/news/home/20261104890700/en/Personalis-Reports-Third-Quarter-Results?ref=bullished.co) tied mainly to the merger agreement. The net loss was $33.8 million in the quarter and $95.5 million for nine months. Cash and short-term investments stood at $190.6 million. The company said it may not sell stock through its at-the-market program, which has about $145.4 million left, while the merger is pending. ## Merck's vote and the Tempus deal Merck signed a voting agreement committing its shares to the Tempus merger. It held about 13% of voting power as of July 20. The filing shows a $76.8 million termination fee Personalis could owe Tempus in specified circumstances, and an equal reverse fee Tempus could owe Personalis. Personalis stockholders get $16.25 per share in value, in Tempus stock with a floor mechanism, and Tempus may pay cash for up to 50% of shares. The antitrust waiting period has expired and the registration statement is effective. Stockholders vote on November 30, and the merger agreement's outside date for closing is April 20, 2027. ### Sources - [10-Q Filing — Personalis (PSNL)](https://www.sec.gov/Archives/edgar/data/0001527753/000119312526447201/psnl-20260930.htm?ref=bullished.co) — SEC EDGAR - [10-Q Filing — Personalis (PSNL), Q2 FY2026 filed 2026-08-04 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001527753/000119312526332817/psnl-20260630.htm?ref=bullished.co) — SEC EDGAR - [Earnings release (8-K Item 2.02, psnl-ex99\_1.htm) — Personalis, filed 2026-11-04](https://www.sec.gov/Archives/edgar/data/0001527753/000119312526447196/psnl-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR - [TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside](https://finance.yahoo.com/healthcare/articles/tem-q3-earnings-call-highlights-140000514.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance - [Personalis: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/11/personalis-q3-earnings-snapshot/?ref=bullished.co) — wtop.com - [Tempus Reports Third Quarter 2026 Results](https://finance.yahoo.com/healthcare/articles/tempus-reports-third-quarter-2026-120000226.html?ref=bullished.co) — Yahoo Finance - [Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop?](https://www.benzinga.com/markets/equities/26/11/62766521/tempus-ai-earnings-ahead-is-the-cathie-wood-stock-set-up-for-a-pop-or-a-drop?ref=bullished.co) — benzinga.com - [Personalis Reports Third Quarter Results](https://www.businesswire.com/news/home/20261104890700/en/Personalis-Reports-Third-Quarter-Results?ref=bullished.co) — businesswire.com ### More on Personalis - [Personalis Tells Holders To Back Tempus Deal Worth $16.25 A Share In Stock, Citing 28% And 64% Premiums](https://www.bullished.co/personalis-tells-holders-to-back-tempus-deal-worth-16-25-a-share-in-stock-citing-28-and-64-bab18df2/) - [Personalis Holders Vote November 30 On Tempus Deal, Which Carries A $48.42 Floor And A $46.00 Walk-Away](https://www.bullished.co/personalis-holders-vote-november-30-on-tempus-deal-which-carries-a-48-42-floor-and-a-46-00-81414cce/) - [Personalis Tells Employees It Does Not Anticipate Layoffs In Pending Tempus Deal](https://www.bullished.co/personalis-tells-employees-it-does-not-anticipate-layoffs-in-pending-tempus-deal-3f348ffa/) [All Personalis (PSNL) coverage →](https://www.bullished.co/tag/psnl/)